Home
/
vTv Therapeutics Inc.
/
Financials
/
Quarterly
vTv Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that vTv Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 12, 2025
Q1
2025
Mar 31, 2025
$0
May 15, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 12, 2025
Q1
2025
Mar 31, 2024
$1.00M
May 15, 2025
Q3
2024
Sep 30, 2023
$0
Nov 12, 2024
Q2
2024
Jun 30, 2023
$0
Aug 8, 2024
Q1
2024
Mar 31, 2023
$0
May 9, 2024
Q3
2023
Sep 30, 2022
$0
Nov 9, 2023
Q2
2023
Jun 30, 2022
$9.0K
Aug 11, 2023
Q1
2023
Mar 31, 2022
$2.00M
May 11, 2023
Q3
2022
Sep 30, 2021
$3.00M
Nov 10, 2022
Q2
2022
Jun 30, 2021
$9.0K
Aug 15, 2022
Q1
2022
Mar 31, 2021
$987.0K
May 12, 2022
Q3
2021
Sep 30, 2020
$7.0K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$8.0K
Aug 4, 2021
Q1
2021
Mar 31, 2020
$8.0K
May 5, 2021
Q3
2020
Sep 30, 2019
$8.0K
Nov 5, 2020
Q2
2020
Jun 30, 2019
$1.83M
Aug 3, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$2.06M
May 15, 2018
Q3
2017
Sep 30, 2017
$15.0K
Nov 1, 2017
Q2
2017
Jun 30, 2017
$13.0K
Aug 2, 2017
Q1
2018
Mar 31, 2017
$30.0K
May 15, 2018
Q3
2017
Sep 30, 2016
$38.0K
Nov 1, 2017
Q2
2017
Jun 30, 2016
$182.0K
Aug 2, 2017
Q1
2017
Mar 31, 2016
$376.0K
May 3, 2017
Q3
2016
Sep 30, 2015
$133.0K
Nov 3, 2016
Q2
2016
Jun 30, 2015
$110.0K
Aug 2, 2016
Q1
2016
Mar 31, 2015
$50.0K
May 13, 2016
Q3
2015
Sep 30, 2014
$400.0K
Nov 13, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($8.70M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($6.05M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($5.09M)
May 15, 2025
Q3
2025
Sep 30, 2024
($4.78M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($5.18M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($4.87M)
May 15, 2025
Q3
2024
Sep 30, 2023
($6.65M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($5.62M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($4.50M)
May 9, 2024
Q3
2023
Sep 30, 2022
($4.26M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($3.15M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($7.01M)
May 11, 2023
Q3
2022
Sep 30, 2021
($1.09M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($608.0K)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($4.24M)
May 12, 2022
Q3
2021
Sep 30, 2020
($1.53M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($3.37M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($4.72M)
May 5, 2021
Q3
2020
Sep 30, 2019
($3.61M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($2.88M)
Aug 3, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($10.70M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($7.72M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($6.50M)
May 15, 2025
Q3
2025
Sep 30, 2024
($6.51M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($7.16M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($5.63M)
May 15, 2025
Q3
2024
Sep 30, 2023
($5.37M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($8.00M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($7.43M)
May 9, 2024
Q3
2023
Sep 30, 2022
($5.69M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($4.03M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($6.48M)
May 11, 2023
Q3
2022
Sep 30, 2021
($1.60M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($4.67M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($4.28M)
May 12, 2022
Q3
2021
Sep 30, 2020
($2.83M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($4.20M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($6.65M)
May 5, 2021
Q3
2020
Sep 30, 2019
($5.43M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($4.79M)
Aug 3, 2020